Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 9/20 | 0.55 |
| ▸ | MET | P08581 | 14/20 | 0.53 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.51 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.51 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | MERTK | Q12866 | 5/20 | 0.48 |
| ▸ | TYRO3 | Q06418 | 4/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2680338 | 0.89 | MET (0.65) | AXLMETRIPK2RIPK1RIPK3 | |
| SCHEMBL199864 | 0.87 | AXL (0.61) | AXLMETRIPK2RIPK1RIPK3 | |
| SCHEMBL783423 | 0.81 | MET (0.65) | AXLMETRIPK2RIPK1RIPK3 | |
| SCHEMBL2742632 | 0.76 | MET (0.77) | AXLMETKDRMERTKTYRO3 | |
| SCHEMBL199488 | 0.76 | MET (0.76) | AXLMETKDR | |
| SCHEMBL1471850 | 0.75 | MET (0.59) | AXLMETRIPK2RIPK1RIPK3 | |
| SCHEMBL783531 | 0.73 | MET (0.71) | AXLMETRIPK2RIPK1RIPK3 | |
| SCHEMBL13861033 | 0.73 | MET (0.65) | AXLMETKDR | |
| SCHEMBL1471740 | 0.72 | AXL (0.56) | AXLMETRIPK2RIPK1RIPK3 | |
| SCHEMBL199597 | 0.72 | MET (0.69) | METKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1881976-B1 | SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | AMGEN INC (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | KIM TAE-SEONG (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | KIM TAE-SEONG (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | HGF, HGFAC, MET | AXL 855/4885MET 3/4885RIPK2 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.